ASTX029
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for ASTX029, covering 2024-08-02 to 2026-02-13. Get the full timeline:
Most recent: Clinical Trial Update: Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms [Phase 1, Phase 2]